Giant Cell Arteritis: The Future of Biologic Therapies

Explore best practices and future advances in primary vasculitides, April 5, 2017


By Leonard Calabrese, DO and Rula Hajj-Ali, MD


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Giant cell arteritis (GCA) is the most common form of systemic vasculitis, affecting an estimated 2.6 in 100,000 people. This unique disease impacts people over the age of 50, most commonly when they reach their 70s.

GCA affects large blood vessels, especially cranial branches of the aorta, and can manifest as headache or jaw pain. It holds the risk of permanent blindness.

Beyond glucocorticoids

While glucocorticoids (GCs) are the cornerstone of therapy and can reduce the risk of visual loss, they’re also toxic, especially for older patients. Relapses are common in GCA, and given the side effects of GCs, adjunctive treatment options are highly necessary. To date, conventional agents such as methotrexate have not been particularly effective.

As the role of biologics in the treatment of rheumatic diseases expands, researchers have studied TNF alpha inhibitors in GCA. Research shows increased expression of TNF alpha in the temporal artery specimens of patients with GCA. But virtually all clinical trials using TNF alpha inhibitors have failed in these patients, and their use is not recommended.

Promise in biologics?

More recently, interleukin-6 inhibitors have showed increasing promise in treating large vessel vasculitis. Tocilizumab (TCZ), currently the only currently approved interleukin-6 receptor antibody, has demonstrated efficacy in a small series of patients with relapsing/refractory GCA and later with patients with newly diagnosed GCA. In 2015, the first randomized controlled trial showed TCZ’s efficacy for inducing and maintaining remission in GCA. Relapse-free survival in the treatment group reached 85 percent versus 20 percent in the placebo group. Frequent adverse events (seven serious events among 20 patients in the treatment arm) necessitate more definitive results on the safety and efficacy of TCZ in GCA. A phase III, multicenter, randomized, double-blind, placebo-controlled study of TCZ in GCA is underway. (GiACTA – identifier: NCT01791153). While not available for peer review, sponsor-released preliminary results suggest efficacy.

Other biologic therapeutics are also of interest in this disease state. A multicenter clinical trial evaluating the efficacy of abatacept for GCA was recently completed. In this study, both relapse-free survival at 12 months (48 percent vs. 31 percent) and median duration of remission (9.9 vs. 3.9 months) were significantly higher among patients receiving abatacept compared with placebo. This remains a pilot study, and replication in larger cohorts is necessary.


Another emerging biologic agent in the treatment of GCA is ustekinumab (a monoclonal antibody to interleukin-12/23p40). A small open study revealed no relapses during treatment with ustekinumab, but results are too preliminary to advocate for routine usage.

Learn more about best practices and future advances

This is an exciting time for clinicians treating GCA. We have witnessed increasing focus on targeted biologic therapy in this disease and hope that investigations will show alternatives to GC treatment.

Clinicians and advanced practitioners interested in vasculitis should join us for a one day satellite symposium, PRIMARY VASCULITIDES: Best Practices and Future Advances, on April 5, 2017, at the Intercontinental Hotel and Convention Center in Cleveland, Ohio. This meeting will cover practical issues of diagnosis, treatment and management of various forms of vasculitis including GCA. The meeting will be chaired by Carol Langford, MD, MHS, and Rula Hajj-Ali, MD, and feature a faculty of international experts.

Sign up for updates and registration information at

This one day symposium precedes the Biologic Therapies VII Summit: Precision Medicine in the Biologic Era, April 6-8, 2017, InterContinental Hotel and Convention Center, Cleveland, Ohio.


This activity has been approved for AMA PRA Category 1 Credit™.

Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology in Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases.

Dr. Hajj-Ali is a staff physician in the Center for Vasculitis Care and Research and the R.J. Fasenmyer Center for Clinical Immunology in the Department of Rheumatic and Immunologic Diseases.

Related Articles

Medical illustration of hand with discolored fingers
Coexistence of Erythromelalgia and Raynaud’s Phenomenon

Treatment strategies require understanding of pathomechanisms

Squamous cell skin cancer
Skin Cancer Risk in Immunosuppressed Patients

Education, prevention strategies and monitoring serves this at-risk group

esophageal plaques
Esophageal Plaques and Systemic Sclerosis

Treatment for scleroderma can sometimes cause esophageal symptoms

Lupus clinic
Coordinated Care, Education and Research

Lupus Clinic providers collaborate to advance treatment and understanding

Psoriatic arthritis
Psoriatic Arthritis: Unlocking the Age Factor

Older Psoriasis Patients May Experience Quicker Transition

Mixed connective tissue disease rash
A Little Bit of Everything: Mixed Connective Tissue Disease

Cleveland Clinic’s Rheumatic Lung Disease program treats patients with complex conditions